Kontour Medical(SH:688314)2024-08-19 07:34Financial Performance - The company achieved a revenue of CNY 153.34 million in the first half of 2024, representing a year-on-year growth of 13.48% [4] - The net profit attributable to shareholders was CNY 48.79 million, an increase of 24.53% compared to the same period last year [4] - The net profit after deducting non-recurring gains and losses was CNY 40.30 million, up by 7.35% year-on-year [5] Business Segments - Neurosurgery business generated revenue of CNY 133.06 million, with a year-on-year growth of 7.97%. PEEK material products contributed CNY 96.22 million, growing by 15.45% and accounting for 65.10% of the main business revenue [5] - The cardiothoracic surgery segment reported revenue of CNY 9.84 million, with PEEK material chest fixation products achieving sales of CNY 9.74 million, a significant increase of 51.53% [5] Market Expansion - The company successfully implemented the Henan Provincial Alliance neurosurgery centralized procurement in Q2 2024, leading to increased penetration of PEEK material products [6] - In the first half of 2024, overseas revenue reached CNY 16.22 million, a growth of 14.97% year-on-year, with the overseas subsidiary BIOPLATE generating CNY 15.03 million, up by 18.53% [8] Product Development - The company is actively expanding its jaw repair business, leveraging academic training and partnerships with experts to enhance market recognition and application [7] - The introduction of the new generation "high-end bone integration implants and accessories" is in the product registration phase, expected to enhance market competitiveness in the dental field [10] Innovation and Future Strategy - The innovative product "3D printed PEEK cranial system" has been successfully applied in multiple surgeries, demonstrating its superior performance and accelerating the commercialization of innovative technologies [10] - The company plans to continue expanding its high-value non-centralized procurement products and optimize production processes to maintain stable gross margins [6]